Chief Medical Officer
Appears in 1 story
Appointed 2026; shepherding SHIELD-AL
The Food and Drug Administration cleared Protego Biopharma to start SHIELD-AL, a pivotal Phase 2/3 trial of PROT-001 in newly diagnosed lambda light chain AL amyloidosis. The oral drug will be tested as an add-on to standard plasma cell-directed therapy, which is currently the backbone of treatment.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
